Najat Khan
Director, CEO and President · 7 filings · Latest: Sep 8, 2026
RECURSION PHARMACEUTICALS, INC.
| Ticker | Owner | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Filing |
|---|---|---|---|---|---|---|---|---|---|
RXRX | Najat Khan | Director, CEO and President | Sep 8, 2026 | Sale | $3.52 | 22,408 | $78.8K | 2,072,890 | |
RXRX | Najat Khan | — | Sep 8, 2026 | Proposed Sale | $3.52 | 22,408 | $78.8K | — | |
RXRX | Najat Khan | Director, CEO and President | Jun 5, 2026 | Sale | $3.58 | 23,588 | $84.5K | 2,175,796 | |
RXRX | Najat Khan | — | Jun 5, 2026 | Proposed Sale | $3.58 | 23,588 | $84.5K | — | |
RXRX | Najat Khan | Director, CEO and President | Mar 9, 2026 | Sale | $3.35 | 28,298 | $94.7K | 2,262,085 | |
RXRX | Najat Khan | — | Mar 9, 2026 | Proposed Sale | $3.35 | 28,298 | $94.7K | — | |
RXRX | Najat Khan | — | Dec 22, 2025 | Proposed Sale | $4.41 | 124,403 | $548.6K | — | |
RXRX | Khan Najat | — | Aug 18, 2025 | Proposed Sale | $5.52 | 36,599 | $202.2K | — |